Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia
暂无分享,去创建一个
P. Dreger | H. Serve | A. Kiani | M. Gramatzki | O. Ottmann | H. Horst | M. Bornhäuser | W. Bethge | B. Wassmann | D. Hoelzer | T. Burmeister | H. Pfeifer | N. Gökbuget | V. Vucinic | M. Stelljes | M. Stadler | C. Faul | D. Beelen | J. Dengler | K. Schäfer-Eckart | R. Schwerdtfeger | B. Kubuschok | P. Brück | E. Lange | V. Vučinić | K. Schäfer‐Eckart | W. Bethge | Christoph Faul | Ethan M. Lange | K. Schäfer-Eckart